Cargando…

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease

Objective. To determine the effects of enzyme replacement therapy (ERT) on the hearing acuity in patients with Fabry disease. Materials. The study sample comprised 34 ears of 17 affected patients who underwent pure-tone audiometry before and after ERT. Methods. The patients were studied in relation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komori, Manabu, Sakurai, Yuika, Kojima, Hiromi, Ohashi, Toya, Moriyama, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817706/ https://www.ncbi.nlm.nih.gov/pubmed/24223040 http://dx.doi.org/10.1155/2013/282487

Ejemplares similares

Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy
por: Morimoto, Satoshi, et al.
Publicado: (2021)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
por: Schiffmann, Raphael, et al.
Publicado: (2009)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy
por: Hongo, Kenichi, et al.
Publicado: (2020)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
por: Weidemann, F, et al.
Publicado: (2013)

Enzyme replacement therapy for Fabry disease: some answers but more questions
por: Alfadhel, Majid, et al.
Publicado: (2011)

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
por: Stefaniak, James D., et al.
Publicado: (2018)

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
por: Deng, Mulan, et al.
Publicado: (2022)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
por: Aoyama, Yumi, et al.
Publicado: (2020)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
por: Tsuboi, Kazuya, et al.
Publicado: (2017)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy
por: Heo, Sun Hee, et al.
Publicado: (2017)

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017)

Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy
por: Dutra-Clarke, Marina, et al.
Publicado: (2020)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease
por: Nguyen Dinh Cat, Aurelie, et al.
Publicado: (2012)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
por: Giugliani, Roberto, et al.
Publicado: (2018)

Aberrant DNA methylation of calcitonin receptor in Fabry patients treated with enzyme replacement therapy
por: Hübner, Anna, et al.
Publicado: (2015)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
por: Boutin, Michel, et al.
Publicado: (2020)

First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland
por: Nowicki, Michał, et al.
Publicado: (2021)

Long-term renal and overall survival of critically ill patients with acute renal injury who received continuous renal replacement therapy
por: Wu, Lingping, et al.
Publicado: (2017)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1ullsn5k0qn26477iochtf397o